Dartmouth-Hitchcock logo
Back
 
Medicine Grand Rounds - Penicillin Allergy Labels: Impact and Improvement

As many as 95% of all patients who report a penicillin allergy are not truly allergic. This presentation discusses the penicillin allergy label and how it influences alternative antibiotic choices which have downstream negative consequences for the patient, communities and healthcare systems. It describes different types of reactions to medications and the cross reactivity of beta-lactam antibiotics. Dr. Blumenthal proposes that allergy evaluation can occur in many settings (it does not have to be in an allergist’s office) and encourages improved education of patients and providers.

Activity Details
Start Date: July 20, 2018
End Date: July 20, 2020
Link: View Presentation

Presenter
  • Kimberly G. Blumenthal, MD, MSc
    Quality Director, Allergy and Immunology
    Massachusetts General Hospital; Assistant Professor of Medicine
    Harvard Medical School 

    Kimberly Blumenthal, MD, MSc is an Allergist/Immunologist and drug allergy researcher at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. She is the Director of Allergy/Immunology Clinical Epidemiology Research within the Division of Rheumatology, Allergy and Immunology. Dr. Blumenthal performs drug allergy research that uses methods of epidemiology, informatics, economics, and decision science. Dr. Blumenthal is recognized nationally for having created innovative approaches to the evaluation of penicillin and cephalosporin antibiotic allergies in the hospital that have since been adopted by other hospitals throughout the US and internationally, broadly referenced, and incorporated into expert recommendations.

Registration

There is no fee for this activity, but to receive credit you must register online and complete the online Attestation and Evaluation form (you must register to access this form).

Learning Outcome

Participants will be able to define the impact of reported penicillin allergies on patients and healthcare systems, including alternative antibiotic choices, costs, testing, clinical evaluation, and messaging; and describe the challenges in penicillin allergy evaluation programs including the education of patients and providers.


Accreditation

Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion



In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the online Attestation of Attendance & Evaluation Form (you must register to access).
Speaker Disclosure

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Penicillin Allergy Labels: Impact and Improvement (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. All potential conflict(s) were resolved.

* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio. 
* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and has other financial interest from Takeda. 

Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:
Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center
clpd.support@hitchcock.org


Type:     Internet Activity (Enduring Material)
14 Registered Users

0